Nurix Therapeutics (NRIX) Financials

$10.64 +0.60 (+5.98%)

Closing price 04:00 PM Eastern

Extended Trading

$9.94 -0.70 (-6.58%)

As of 07:10 PM Eastern

Annual Income Statements for Nurix Therapeutics

This table shows Nurix Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	11/30/2024	11/30/2023	11/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-194	-144	-180
Consolidated Net Income / (Loss)	-194	-144	-180
Net Income / (Loss) Continuing Operations	-194	-144	-180
Total Pre-Tax Income	-193	-144	-180
Total Operating Income	-213	-155	-184
Total Gross Profit	55	77	39
Total Revenue	55	77	39
Operating Revenue	55	77	39
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	268	232	222
Selling, General & Admin Expense	46	43	38
Research & Development Expense	222	189	184
Total Other Income / (Expense), net	20	11	3.51
Interest & Investment Income	20	11	3.51
Income Tax Expense	0.27	0.00	0.00
Basic Earnings per Share	($2.88)	($2.65)	($3.71)
Weighted Average Basic Shares Outstanding	67.12M	54.34M	48.61M
Diluted Earnings per Share	($2.88)	($2.65)	($3.71)
Weighted Average Diluted Shares Outstanding	67.12M	54.34M	48.61M
Weighted Average Basic & Diluted Shares Outstanding	75.89M	48.89M	47.27M
Cash Dividends to Common per Share	$0.00	-	-

This table shows Nurix Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	2/28/2025	11/30/2024	8/31/2024	5/31/2024	2/29/2024	11/30/2023	8/31/2023	5/31/2023	2/28/2023	11/30/2022	8/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-56	-59	-49	-45	-42	-42	-37	-24	-41	-47	-46
Consolidated Net Income / (Loss)	-56	-59	-49	-45	-42	-42	-37	-24	-41	-47	-46
Net Income / (Loss) Continuing Operations	-56	-59	-49	-45	-42	-42	-37	-24	-41	-47	-46
Total Pre-Tax Income	-56	-59	-49	-44	-41	-42	-37	-24	-41	-47	-46
Total Operating Income	-63	-65	-55	-49	-45	-45	-40	-27	-43	-49	-47
Total Gross Profit	18	13	13	12	17	15	18	31	13	6.78	11
Total Revenue	18	13	13	12	17	15	18	31	13	6.78	11
Operating Revenue	18	-	13	12	-	-	18	31	-	6.78	11
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	81	78	67	61	62	60	58	57	56	55	58
Selling, General & Admin Expense	12	11	12	12	12	11	11	12	9.82	9.37	9.75
Research & Development Expense	70	67	55	49	50	50	48	46	46	46	48
Total Other Income / (Expense), net	6.51	6.12	5.74	4.08	3.79	3.38	3.03	2.49	2.22	1.97	1.01
Interest & Investment Income	6.51	6.12	5.74	4.08	3.79	3.38	3.03	2.49	2.22	1.97	1.01
Income Tax Expense	0.00	0.01	0.08	0.09	0.09	-	0.00	0.00	0.00	-	-
Basic Earnings per Share	($0.67)	($0.74)	($0.67)	($0.71)	($0.76)	($0.77)	($0.68)	($0.45)	($0.75)	($0.85)	($0.90)
Weighted Average Basic Shares Outstanding	83.56M	67.12M	72.78M	62.38M	54.90M	54.34M	54.39M	54.26M	54.03M	48.61M	50.87M
Diluted Earnings per Share	($0.67)	($0.74)	($0.67)	($0.71)	($0.76)	($0.77)	($0.68)	($0.45)	($0.75)	($0.85)	($0.90)
Weighted Average Diluted Shares Outstanding	83.56M	67.12M	72.78M	62.38M	54.90M	54.34M	54.39M	54.26M	54.03M	48.61M	50.87M
Weighted Average Basic & Diluted Shares Outstanding	76.24M	75.89M	70.84M	64.41M	49.15M	48.89M	48.50M	48.20M	47.45M	47.27M	47.15M
Cash Dividends to Common per Share	$0.00	-	-	-	$0.00	-	-	-	$0.00	-	-

This table details how cash moves in and out of Nurix Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	11/30/2024	11/30/2023	11/30/2022
Net Change in Cash & Equivalents	55	-9.85	-15
Net Cash From Operating Activities	-173	-81	-160
Net Cash From Continuing Operating Activities	-173	-81	-160
Net Income / (Loss) Continuing Operations	-194	-144	-180
Consolidated Net Income / (Loss)	-194	-144	-180
Depreciation Expense	9.32	7.53	5.35
Amortization Expense	-4.18	0.70	5.89
Non-Cash Adjustments To Reconcile Net Income	34	34	28
Changes in Operating Assets and Liabilities, net	-18	20	-19
Net Cash From Investing Activities	-258	68	27
Net Cash From Continuing Investing Activities	-258	68	27
Purchase of Property, Plant & Equipment	-9.27	-8.40	-12
Purchase of Investments	-708	-246	-239
Sale and/or Maturity of Investments	460	323	279
Net Cash From Financing Activities	486	3.22	117
Net Cash From Continuing Financing Activities	486	3.22	117
Repurchase of Preferred Equity	-0.02	0.00	0.00
Issuance of Common Equity	481	2.23	116
Other Financing Activities, net	5.06	0.99	1.08

This table details how cash moves in and out of Nurix Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	2/28/2025	11/30/2024	8/31/2024	5/31/2024	2/29/2024	11/30/2023	8/31/2023	5/31/2023	2/28/2023	11/30/2022	8/31/2022
Net Change in Cash & Equivalents	-34	11	-18	67	-4.81	12	-17	25	-31	17	6.02
Net Cash From Operating Activities	-61	-49	-42	-40	-42	27	-41	-18	-48	-38	-46
Net Cash From Continuing Operating Activities	-61	-49	-42	-40	-42	27	-41	-18	-48	-38	-46
Net Income / (Loss) Continuing Operations	-56	-59	-49	-45	-42	-42	-37	-24	-41	-47	-46
Consolidated Net Income / (Loss)	-56	-59	-49	-45	-42	-42	-37	-24	-41	-47	-46
Depreciation Expense	2.35	2.55	2.39	2.33	2.05	1.93	1.95	1.90	1.75	1.62	1.46
Amortization Expense	-1.78	-1.74	-1.95	-0.40	-0.09	-0.15	-0.21	0.45	0.61	0.77	1.51
Non-Cash Adjustments To Reconcile Net Income	8.72	8.54	9.04	8.85	7.82	8.04	8.89	8.76	8.54	8.30	6.99
Changes in Operating Assets and Liabilities, net	-14	0.45	-2.70	-5.94	-10	59	-15	-5.30	-19	-1.92	-11
Net Cash From Investing Activities	26	-141	-21	-131	36	-14	23	44	16	55	-63
Net Cash From Continuing Investing Activities	26	-141	-21	-131	36	-14	23	44	16	55	-63
Purchase of Property, Plant & Equipment	-3.49	-2.11	-2.35	-1.94	-2.88	-2.59	-2.46	-1.08	-2.28	-2.57	-3.42
Purchase of Investments	-110	-298	-130	-225	-55	-88	-75	-61	-23	-27	-132
Sale and/or Maturity of Investments	139	160	111	96	93	77	100	106	41	84	73
Net Cash From Financing Activities	1.47	201	46	238	1.62	0.01	1.70	0.03	1.48	-0.14	115
Net Cash From Continuing Financing Activities	1.47	201	46	238	1.62	0.01	1.70	0.03	1.48	-0.14	115
Issuance of Common Equity	1.25	199	43	238	1.27	-	0.78	-	1.45	-0.18	115
Other Financing Activities, net	0.22	1.45	3.04	0.22	0.36	0.01	0.93	0.03	0.03	0.05	0.17

This table presents Nurix Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	11/30/2024	11/30/2023	11/30/2022
Total Assets	669	356	417
Total Current Assets	619	296	318
Cash & Equivalents	110	55	64
Short-Term Investments	500	233	245
Prepaid Expenses	9.80	7.60	9.31
Plant, Property, & Equipment, net	18	17	17
Total Noncurrent Assets	32	43	81
Long-Term Investments	0.00	7.42	64
Other Noncurrent Operating Assets	32	36	17
Total Liabilities & Shareholders' Equity	669	356	417
Total Liabilities	142	155	113
Total Current Liabilities	96	87	71
Accounts Payable	11	6.40	5.06
Accrued Expenses	38	25	22
Current Deferred Revenue	38	48	38
Other Current Liabilities	8.01	7.49	5.53
Total Noncurrent Liabilities	46	68	42
Noncurrent Deferred Revenue	26	45	36
Other Noncurrent Operating Liabilities	20	23	6.43
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	527	200	304
Total Preferred & Common Equity	527	200	304
Preferred Stock	0.00	0.00	0.00
Total Common Equity	527	200	304
Common Stock	1,266	746	709
Retained Earnings	-739	-545	-401
Accumulated Other Comprehensive Income / (Loss)	0.15	-0.66	-4.32

This table presents Nurix Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	2/28/2025	8/31/2024	5/31/2024	2/29/2024	8/31/2023	5/31/2023	2/28/2023	8/31/2022
Total Assets	615	514	511	313	308	351	370	459
Total Current Assets	564	456	450	251	268	290	288	355
Cash & Equivalents	76	99	117	50	42	59	34	48
Short-Term Investments	474	349	326	194	217	222	244	297
Prepaid Expenses	14	7.99	7.08	6.98	7.10	8.84	11	10
Plant, Property, & Equipment, net	18	17	19	18	17	18	18	17
Total Noncurrent Assets	33	40	42	44	24	42	64	88
Other Noncurrent Operating Assets	33	31	33	34	14	15	16	19
Total Liabilities & Shareholders' Equity	615	514	511	313	308	351	370	459
Total Liabilities	134	137	140	144	74	91	96	117
Total Current Liabilities	90	86	81	88	61	72	65	68
Accounts Payable	8.40	3.92	2.81	5.92	2.19	4.53	5.63	6.05
Accrued Expenses	44	28	23	28	22	18	15	20
Current Deferred Revenue	31	48	47	46	32	44	38	36
Other Current Liabilities	6.64	6.55	7.93	7.31	5.36	5.58	5.56	5.50
Total Noncurrent Liabilities	44	50	60	56	13	18	31	49
Noncurrent Deferred Revenue	24	30	39	34	10	15	26	42
Other Noncurrent Operating Liabilities	20	21	21	22	2.64	3.76	5.11	7.75
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	481	377	371	169	234	260	274	343
Total Preferred & Common Equity	481	377	371	169	234	260	274	343
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	481	377	371	169	234	260	274	343
Common Stock	1,276	1,057	1,002	756	738	728	719	701
Retained Earnings	-795	-680	-631	-587	-503	-466	-442	-355
Accumulated Other Comprehensive Income / (Loss)	0.23	0.34	-0.14	-0.35	-1.23	-1.90	-3.25	-3.74

This table displays calculated financial ratios and metrics derived from Nurix Therapeutics' official financial filings.

Metric	2024	2023	2022
Period end date	11/30/2024	11/30/2023	11/30/2022
Growth Metrics	-	-	-
Revenue Growth	-29.15%	99.31%	29.84%
EBITDA Growth	-41.58%	14.95%	-56.80%
EBIT Growth	-37.38%	15.67%	-55.97%
NOPAT Growth	-37.38%	15.67%	-55.97%
Net Income Growth	-34.47%	20.19%	-53.90%
EPS Growth	-8.68%	28.57%	-35.90%
Operating Cash Flow Growth	-112.11%	49.09%	-89.42%
Free Cash Flow Firm Growth	-94.34%	44.64%	-129.50%
Invested Capital Growth	12.91%	-36.80%	23.49%
Revenue Q/Q Growth	-3.32%	12.21%	-1.56%
EBITDA Q/Q Growth	-10.82%	1.84%	-6.52%
EBIT Q/Q Growth	-9.98%	2.12%	-6.20%
NOPAT Q/Q Growth	-9.98%	2.12%	-6.20%
Net Income Q/Q Growth	-9.38%	3.20%	-5.26%
EPS Q/Q Growth	1.03%	2.93%	0.00%
Operating Cash Flow Q/Q Growth	-77.66%	44.27%	-4.61%
Free Cash Flow Firm Q/Q Growth	-79.61%	43.53%	-6.91%
Invested Capital Q/Q Growth	-2.38%	-171.60%	2.44%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-381.10%	-190.72%	-446.92%
Operating Margin	-390.52%	-201.41%	-476.01%
EBIT Margin	-390.52%	-201.41%	-476.01%
Profit (Net Income) Margin	-354.85%	-186.98%	-466.93%
Tax Burden Percent	100.14%	100.00%	100.00%
Interest Burden Percent	90.74%	92.83%	98.09%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-53.22%	-57.10%	-55.84%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-41.57%	-40.15%	-41.16%
Return on Assets (ROA)	-37.77%	-37.28%	-40.37%
Return on Common Equity (ROCE)	-53.22%	-57.10%	-55.84%
Return on Equity Simple (ROE_SIMPLE)	-36.73%	-71.80%	-59.39%
Net Operating Profit after Tax (NOPAT)	-149	-109	-129
NOPAT Margin	-273.37%	-140.99%	-333.20%
Net Nonoperating Expense Percent (NNEP)	-9.82%	-10.59%	-12.82%
Return On Investment Capital (ROIC_SIMPLE)	-28.30%	-54.14%	-42.38%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	84.23%	55.73%	98.37%
R&D to Revenue	406.30%	245.69%	477.64%
Operating Expenses to Revenue	490.52%	301.41%	576.01%
Earnings before Interest and Taxes (EBIT)	-213	-155	-184
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-208	-147	-173
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.97	1.50	1.92
Price to Tangible Book Value (P/TBV)	2.97	1.50	1.92
Price to Revenue (P/Rev)	28.71	3.92	15.12
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	17.54	0.08	5.47
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.24	-1.33	-1.25
Leverage Ratio	1.41	1.53	1.38
Compound Leverage Factor	1.28	1.42	1.36
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	5.03	-1.50	1.10
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	6.46	3.40	4.51
Quick Ratio	6.36	3.31	4.38
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-161	-83	-150
Operating Cash Flow to CapEx	-1,861.15%	-968.52%	-1,305.19%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.11	0.20	0.09
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	3.16	4.53	2.71
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-83	-95	-69
Invested Capital Turnover	-0.61	-0.94	-0.48
Increase / (Decrease) in Invested Capital	12	-26	21
Enterprise Value (EV)	957	6.36	211
Market Capitalization	1,566	302	584
Book Value per Share	$7.44	$4.13	$6.44
Tangible Book Value per Share	$7.44	$4.13	$6.44
Total Capital	527	200	304
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-610	-295	-373
Capital Expenditures (CapEx)	9.27	8.40	12
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-86	-79	-61
Debt-free Net Working Capital (DFNWC)	524	209	248
Net Working Capital (NWC)	524	209	248
Net Nonoperating Expense (NNE)	44	35	52
Net Nonoperating Obligations (NNO)	-610	-295	-373
Total Depreciation and Amortization (D&A)	5.14	8.23	11
Debt-free, Cash-free Net Working Capital to Revenue	-157.75%	-103.09%	-158.82%
Debt-free Net Working Capital to Revenue	959.75%	270.88%	641.50%
Net Working Capital to Revenue	959.75%	270.88%	641.50%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.88)	($2.65)	($3.71)
Adjusted Weighted Average Basic Shares Outstanding	67.12M	54.34M	48.61M
Adjusted Diluted Earnings per Share	($2.88)	($2.65)	($3.71)
Adjusted Weighted Average Diluted Shares Outstanding	67.12M	54.34M	48.61M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	75.89M	48.89M	47.27M
Normalized Net Operating Profit after Tax (NOPAT)	-149	-109	-129
Normalized NOPAT Margin	-273.37%	-140.99%	-333.20%
Pre Tax Income Margin	-354.36%	-186.98%	-466.93%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Nurix Therapeutics' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	2/28/2025	11/30/2024	8/31/2024	5/31/2024	2/29/2024	11/30/2023	8/31/2023	5/31/2023	2/28/2023	11/30/2022	8/31/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	11.26%	-12.37%	-31.84%	-60.58%	30.75%	123.49%	71.13%	168.33%	31.85%	-8.29%	5.26%
EBITDA Growth	-43.99%	-46.62%	-41.54%	-90.84%	-6.58%	5.96%	12.52%	42.71%	-1.60%	-29.57%	-62.91%
EBIT Growth	-39.02%	-42.62%	-36.49%	-81.36%	-5.28%	6.89%	14.35%	41.45%	-0.49%	-28.29%	-61.11%
NOPAT Growth	-39.02%	-42.62%	-36.49%	-81.36%	-5.28%	6.89%	14.35%	41.45%	-0.49%	-28.29%	-61.11%
Net Income Growth	-35.73%	-39.55%	-32.38%	-83.49%	-1.93%	10.19%	19.09%	46.53%	4.23%	-23.91%	-58.52%
EPS Growth	11.84%	3.90%	1.47%	-57.78%	-1.33%	9.41%	24.44%	55.45%	21.05%	0.00%	-38.46%
Operating Cash Flow Growth	-45.62%	-282.66%	-2.54%	-114.98%	13.42%	170.32%	11.18%	43.89%	-13.66%	-22.79%	-54.50%
Free Cash Flow Firm Growth	-2,696.61%	-824.26%	111.73%	98.33%	104.02%	88.76%	-23.83%	-8.07%	3.38%	-488.93%	-193.38%
Invested Capital Growth	19.61%	12.91%	-131.03%	-67.96%	-65.95%	-36.80%	50.86%	40.64%	35.37%	23.49%	21.19%
Revenue Q/Q Growth	38.91%	5.53%	4.10%	-27.09%	9.41%	-17.91%	-39.80%	141.83%	87.01%	-37.14%	-5.61%
EBITDA Q/Q Growth	2.43%	-17.86%	-16.23%	-7.74%	0.65%	-13.77%	-56.72%	39.83%	12.34%	-5.84%	-2.62%
EBIT Q/Q Growth	2.77%	-18.40%	-12.51%	-7.34%	0.25%	-13.30%	-49.49%	37.69%	11.78%	-4.22%	-2.19%
NOPAT Q/Q Growth	2.77%	-18.40%	-12.51%	-7.34%	0.25%	-13.30%	-49.49%	37.69%	11.78%	-4.22%	-2.19%
Net Income Q/Q Growth	3.75%	-19.60%	-9.90%	-7.29%	1.04%	-13.45%	-52.33%	40.40%	12.81%	-2.21%	-0.68%
EPS Q/Q Growth	9.46%	-10.45%	5.63%	6.58%	1.30%	-13.24%	-51.11%	40.00%	11.76%	5.56%	10.89%
Operating Cash Flow Q/Q Growth	-25.30%	-15.59%	-6.23%	5.35%	-257.18%	164.88%	-122.71%	61.88%	-27.66%	18.04%	-40.69%
Free Cash Flow Firm Q/Q Growth	-5.69%	-864.37%	963.75%	-137.21%	137.62%	90.30%	-23.14%	10.60%	-5.24%	-6.87%	-7.47%
Invested Capital Q/Q Growth	16.74%	-2.38%	1.42%	4.34%	9.81%	-171.60%	28.33%	5.48%	25.65%	2.44%	13.43%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-337.58%	-480.63%	-430.34%	-385.44%	-260.84%	-287.26%	-207.25%	-79.61%	-319.98%	-682.63%	-405.42%
Operating Margin	-340.67%	-486.73%	-433.83%	-401.42%	-272.65%	-299.06%	-216.67%	-87.25%	-338.60%	-717.82%	-432.93%
EBIT Margin	-340.67%	-486.73%	-433.83%	-401.42%	-272.65%	-299.06%	-216.67%	-87.25%	-338.60%	-717.82%	-432.93%
Profit (Net Income) Margin	-305.38%	-440.75%	-388.91%	-368.39%	-250.33%	-276.77%	-200.26%	-79.14%	-321.11%	-688.74%	-423.58%
Tax Burden Percent	100.00%	100.01%	100.17%	100.20%	100.22%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	89.64%	90.54%	89.49%	91.59%	91.62%	92.55%	92.43%	90.70%	94.83%	95.95%	97.84%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-64.16%	-53.22%	-57.96%	-52.33%	-65.37%	-57.10%	-51.60%	-59.79%	-61.58%	-55.84%	-47.74%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-41.43%	-51.81%	-59.57%	-58.05%	-64.60%	-59.62%	-38.74%	-14.27%	-34.95%	-62.06%	-35.67%
Return on Assets (ROA)	-37.14%	-46.91%	-53.40%	-53.27%	-59.31%	-55.18%	-35.80%	-12.95%	-33.14%	-59.55%	-34.90%
Return on Common Equity (ROCE)	-64.16%	-53.22%	-57.96%	-52.33%	-65.37%	-57.10%	-51.60%	-59.79%	-61.58%	-55.84%	-47.74%
Return on Equity Simple (ROE_SIMPLE)	-43.33%	0.00%	-46.96%	-44.51%	-85.77%	0.00%	-63.60%	-60.57%	-65.16%	0.00%	-50.02%
Net Operating Profit after Tax (NOPAT)	-44	-45	-38	-34	-32	-32	-28	-19	-30	-34	-33
NOPAT Margin	-238.47%	-340.71%	-303.68%	-281.00%	-190.86%	-209.34%	-151.67%	-61.08%	-237.02%	-502.48%	-303.05%
Net Nonoperating Expense Percent (NNEP)	-3.07%	-2.94%	-2.95%	-2.78%	-3.40%	-3.06%	-2.63%	-1.69%	-3.00%	-3.14%	-2.96%
Return On Investment Capital (ROIC_SIMPLE)	-9.15%	-8.59%	-	-	-	-15.83%	-	-	-	-11.22%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	63.16%	80.68%	93.09%	96.84%	71.14%	71.11%	57.52%	38.07%	77.42%	138.10%	90.33%
R&D to Revenue	377.52%	506.05%	440.75%	404.58%	301.51%	327.94%	259.14%	149.18%	361.18%	679.73%	442.60%
Operating Expenses to Revenue	440.67%	586.73%	533.83%	501.42%	372.65%	399.06%	316.67%	187.25%	438.60%	817.82%	532.93%
Earnings before Interest and Taxes (EBIT)	-63	-65	-55	-49	-45	-45	-40	-27	-43	-49	-47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-62	-64	-54	-47	-43	-44	-38	-24	-41	-46	-44
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.44	2.97	4.31	2.09	3.55	1.50	1.75	1.85	1.63	1.92	2.16
Price to Tangible Book Value (P/TBV)	2.44	2.97	4.31	2.09	3.55	1.50	1.75	1.85	1.63	1.92	2.16
Price to Revenue (P/Rev)	20.78	28.71	28.77	12.43	7.41	3.92	5.97	7.88	10.69	15.12	18.86
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	11.04	17.54	20.66	5.16	4.26	0.08	2.05	2.81	2.88	5.47	8.32
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.24	-1.24	-1.19	-1.21	-1.31	-1.33	-1.18	-1.25	-1.23	-1.25	-1.22
Leverage Ratio	1.43	1.41	1.35	1.37	1.54	1.53	1.33	1.41	1.39	1.38	1.33
Compound Leverage Factor	1.28	1.28	1.20	1.25	1.41	1.42	1.23	1.28	1.32	1.33	1.30
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	4.11	5.76	5.89	2.26	0.28	-0.48	1.62	1.98	1.57	2.17	3.22
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.26	6.46	5.28	5.57	2.86	3.40	4.36	4.01	4.44	4.51	5.26
Quick Ratio	6.11	6.36	5.19	5.49	2.78	3.31	4.24	3.89	4.27	4.38	5.10
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-61	-58	7.52	-0.87	2.34	-6.22	-64	-52	-58	-55	-52
Operating Cash Flow to CapEx	-1,752.86%	-2,315.96%	-1,797.06%	-2,049.82%	-1,454.61%	1,032.46%	-1,672.75%	-1,710.09%	-2,127.89%	-1,479.73%	-1,354.83%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.12	0.11	0.14	0.14	0.24	0.20	0.18	0.16	0.10	0.09	0.08
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	3.11	3.16	3.35	3.36	4.55	4.53	4.15	3.58	2.67	2.71	3.01
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-69	-83	-81	-82	-86	-95	-35	-49	-52	-69	-71
Invested Capital Turnover	-0.73	-0.61	-0.98	-0.95	-1.18	-0.94	-1.29	-0.93	-0.64	-0.48	-0.49
Increase / (Decrease) in Invested Capital	17	12	-46	-33	-34	-26	36	33	28	21	19
Enterprise Value (EV)	623	957	1,166	322	345	6.36	141	172	120	211	326
Market Capitalization	1,172	1,566	1,623	774	599	302	410	480	446	584	740
Book Value per Share	$6.34	$7.44	$5.85	$7.54	$3.07	$4.13	$4.85	$5.48	$5.80	$6.44	$7.28
Tangible Book Value per Share	$6.34	$7.44	$5.85	$7.54	$3.07	$4.13	$4.85	$5.48	$5.80	$6.44	$7.28
Total Capital	481	527	377	371	169	200	234	260	274	304	343
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-550	-610	-458	-453	-254	-295	-269	-309	-326	-373	-414
Capital Expenditures (CapEx)	3.49	2.11	2.35	1.94	2.88	2.59	2.46	1.08	2.28	2.57	3.42
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-76	-86	-78	-74	-81	-79	-52	-63	-54	-61	-57
Debt-free Net Working Capital (DFNWC)	474	524	370	369	163	209	206	218	223	248	287
Net Working Capital (NWC)	474	524	370	369	163	209	206	218	223	248	287
Net Nonoperating Expense (NNE)	12	13	11	11	9.86	10	8.97	5.54	11	13	13
Net Nonoperating Obligations (NNO)	-550	-610	-458	-453	-254	-295	-269	-309	-326	-373	-414
Total Depreciation and Amortization (D&A)	0.57	0.81	0.44	1.93	1.96	1.79	1.74	2.34	2.36	2.39	2.97
Debt-free, Cash-free Net Working Capital to Revenue	-134.65%	-157.75%	-138.78%	-118.29%	-99.70%	-103.09%	-76.37%	-104.09%	-128.79%	-158.82%	-145.53%
Debt-free Net Working Capital to Revenue	839.67%	959.75%	655.30%	592.97%	201.94%	270.88%	300.91%	357.35%	535.97%	641.50%	732.34%
Net Working Capital to Revenue	839.67%	959.75%	655.30%	592.97%	201.94%	270.88%	300.91%	357.35%	535.97%	641.50%	732.34%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.67)	($0.74)	($0.67)	($0.71)	($0.76)	($0.77)	($0.68)	($0.45)	($0.75)	($0.85)	($0.90)
Adjusted Weighted Average Basic Shares Outstanding	83.56M	67.12M	72.78M	62.38M	54.90M	54.34M	54.39M	54.26M	54.03M	48.61M	50.87M
Adjusted Diluted Earnings per Share	($0.67)	($0.74)	($0.67)	($0.71)	($0.76)	($0.77)	($0.68)	($0.45)	($0.75)	($0.85)	($0.90)
Adjusted Weighted Average Diluted Shares Outstanding	83.56M	67.12M	72.78M	62.38M	54.90M	54.34M	54.39M	54.26M	54.03M	48.61M	50.87M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	76.24M	75.89M	70.84M	64.41M	49.15M	48.89M	48.50M	48.20M	47.45M	47.27M	47.15M
Normalized Net Operating Profit after Tax (NOPAT)	-44	-45	-38	-34	-32	-32	-28	-19	-30	-34	-33
Normalized NOPAT Margin	-238.47%	-340.71%	-303.68%	-281.00%	-190.86%	-209.34%	-151.67%	-61.08%	-237.02%	-502.48%	-303.05%
Pre Tax Income Margin	-305.38%	-440.69%	-388.26%	-367.65%	-249.79%	-276.77%	-200.26%	-79.14%	-321.11%	-688.74%	-423.58%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Nurix Therapeutics' Financials

When does Nurix Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Nurix Therapeutics' financial year ends in November. Their financial year 2024 ended on November 30, 2024.

How has Nurix Therapeutics' net income changed over the last 2 years?

Nurix Therapeutics' net income appears to be on an upward trend, with a most recent value of -$193.57 million in 2024, rising from -$180.36 million in 2022. The previous period was -$143.95 million in 2023. See Nurix Therapeutics' forecast for analyst expectations on what’s next for the company.

What is Nurix Therapeutics's operating income?

Nurix Therapeutics's total operating income in 2024 was -$213.03 million, based on the following breakdown:

Total Gross Profit: $54.55 million
Total Operating Expenses: $267.58 million

How has Nurix Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Nurix Therapeutics' total revenue changed from $38.63 million in 2022 to $54.55 million in 2024, a change of 41.2%.

How much debt does Nurix Therapeutics have?

Nurix Therapeutics' total liabilities were at $142.35 million at the end of 2024, a 8.2% decrease from 2023, and a 25.9% increase since 2022.

How much cash does Nurix Therapeutics have?

In the past 2 years, Nurix Therapeutics' cash and equivalents has ranged from $54.63 million in 2023 to $110.00 million in 2024, and is currently $110.00 million as of their latest financial filing in 2024.

How has Nurix Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Nurix Therapeutics' book value per share changed from 6.44 in 2022 to 7.44 in 2024, a change of 15.5%.

Related Companies

This page (NASDAQ:NRIX) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nurix Therapeutics (NRIX) Financials

Frequently Asked Questions About Nurix Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nurix Therapeutics (NRIX) Financials

Annual Income Statements for Nurix Therapeutics

Quarterly Income Statements for Nurix Therapeutics

Annual Cash Flow Statements for Nurix Therapeutics

Quarterly Cash Flow Statements for Nurix Therapeutics

Annual Balance Sheets for Nurix Therapeutics

Quarterly Balance Sheets for Nurix Therapeutics

Annual Metrics And Ratios for Nurix Therapeutics

Quarterly Metrics And Ratios for Nurix Therapeutics

Frequently Asked Questions About Nurix Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools